{
    "symbol": "VNDA",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-02 22:35:04",
    "content": " Total revenues for the first nine months of 2022 were $189.9 million, a 5% decrease compared to $200.7 million for the same period in 2021. For the first nine months of 2022, being recorded a net loss of 600,000 compared to net income of $26.1 million for the same period in 2021. Operating expenses for the first nine months of 2022 were $190.2 million, compared to $167.1 million for the first nine months of 2021. The increase in R&D expenses was primarily driven by increases related to our late-stage clinical program for Fanapt, as well as a $3 million upfront fee expense in the third quarter of 2022 in consideration for entering into the previously announced OliPass agreement. In U.S. cash, cash equivalents and marketable securities referred to US cash as of September 30, 2022 was $454.8 million, representing an increase of $48.8 million in cash, or 12% as compared to September 30, 2021, and an increase of $22 million or 5% as compared to December 31, 2021. Total revenues for the third quarter of 2022 were $65.3 million, a 7% decrease compared to $70.1 million for the third quarter of 2021. HETLIOZ net product sales were $41.3 million for the third quarter of 2020, a 9% decrease compared to $45.6 million for the third quarter of 2021. Fanapt net product sales for the third quarter of 2022 were $24 million, a 2% decrease compared to $24.5 million for the third quarter of 2021. For the third quarter of 2022, Vanda recorded net income of $3.3 million, compared to net income of $7.8 million for the third quarter of 2021. The increase in R&D expenses was driven primarily by costs associated with our late-stage clinical programs for Fanapt antidepressant and the $3 million upfront fee expense in the third quarter of 2022 in consideration of the previously discussed slowly past agreement."
}